Table 2. Changes in Clinical Parameters After Sitagliptin Treatment (n = 3,201) .
| Baseline | At 1 month | At 3 months | At 6 months | P value* | |
|---|---|---|---|---|---|
| Body mass index (kg/m2) | 25.1 ± 4.3 | 25.2 ± 4.3 | 25.2 ± 4.3 | 25.6 ± 4.3 | NS |
| n | 2,845 | 1,937 | 2,026 | 1,512 | |
| HbA1c (NGSP) (%) | 7.44 ± 1.20 | 7.07 ± 1.03** | 6.75 ± 0.92** | 6.73 ± 0.99** | < 0.0001 |
| n | 3,132 | 2,848 | 2,959 | 2,946 | |
| Random blood glucose level (mmo/L) | 9.69 ± 3.56 | 8.42 ± 2.88** | 8.32 ± 2.78** | 8.47 ± 2.91** | < 0.0001 |
| n | 3,102 | 2,858 | 2,946 | 2,923 |
Data are mean ± SD or number of subjects. *Changes in clinical parameters after sitagliptin treatment were evaluated by analysis of variance using mixed effects model. **Comparison between baseline value and each value at 1, 3 and 6 months, by Student’s t-test. P < 0.05. NGSP: National Glycohemoglobin Standardization Program.